Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All provided claims are directly supported by the FDA label fetal toxicity/pregnancy sections (5.1 and 8.1) with no contradictions or unsafe omissions identified.
Category Scores
Accurate Statements
Sacubitril and valsartan can cause fetal harm; use during the 2nd and 3rd trimesters reduces fetal renal function and increases fetal/neonatal morbidity and death, and pregnancy should prompt discontinuation and consideration of alternatives.
Supported by label 5.1 (fetal harm; 2nd/3rd trimester RAAS effects reduce fetal renal function and increase fetal/neonatal morbidity and death; discontinue and consider alternatives when pregnancy detected) and 8.1 (risk summary and clinical considerations describing fetal/neonatal adverse reactions and guidance to discontinue/consider alternatives).
Claim includes that oligohydramnios and downstream serious fetal/neonatal outcomes are part of the pregnancy risk described in the label (via 8.1 clinical considerations).
Supported by label 8.1 (Clinical Considerations) describing oligohydramnios leading to reduced fetal renal function, fetal lung hypoplasia, skeletal deformities, hypotension, and death; and neonatal observation/support guidance.
Unsupported Statements
Contradictions
Important Omissions
The evaluation does not explicitly mention the label’s specific counseling/monitoring elements for pregnancy in the ‘Patient Counseling Information’ (17) such as advising childbearing-age female patients and reporting pregnancies to physicians as soon as possible.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided claim is consistent with the label’s fetal toxicity warning and pregnancy management guidance; no contradicting safety statements were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Does not explicitly include label ‘Patient Counseling Information’ (17) pregnancy communication/reporting guidance.
Suggested Improvement
Add that female patients of childbearing age should be advised of pregnancy consequences and to report pregnancies to their physicians as soon as possible per label 17.